BeiGene to Present P-III Trial (RATIONALE 315) Results of Tislelizumab for Resectable Non-Small Cell Lung Cancer at ESMO Congress 2023
Shots:
- The P-III trial (RATIONALE 315) evaluating neoadjuvant tislelizumab + Pt-based doublet CT vs PBO + neoadjuvant Pt-based doublet CT in a ratio (1:1) in 453 patients with resectable Stage II or IIIA NSCLC
- The study met its dual 1EPs of MPR by BIPR and EFS by BICR, 56.2% of patients treated with tislelizumab + CT before surgery achieved MPR vs 15.0% with CT alone, 40.7% vs 5.7% achieved pCR. The combination therapy was generally well tolerated with no new safety signals
- At the prespecified interim analysis, the tislelizumab-based regimen showed a significant improvement in EFS per assessment by BICR. The results will be submitted for presentation at an upcoming medical conference
Ref: Businesswire | Image: BeiGene
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
